Compounds > 6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxy-1-benzopyran-2-one

Page last updated: 2024-08-01 21:57:08

6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxy-1-benzopyran-2-one

Description

6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxy-1-benzopyran-2-one : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	6215536
CHEMBL ID	1539772
CHEBI ID	121090

Synonyms (11)

Synonym
MLS001193356
smr000592260
CHEBI:121090
6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxychromen-2-one
HMS2890E23
AB00752180-01
CHEMBL1539772
Q27209333
6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxy-1-benzopyran-2-one
Z44566160
AKOS034354866

Drug Classes (1)

Class	Description
hydroxycoumarin	Any coumarin carrying at least one hydroxy substituent.

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	12.5893	AID485294
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	22.3872	AID485281
glp-1 receptor, partial	Homo sapiens (human)	Potency	10.0000	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	AID588456
TDP1 protein	Homo sapiens (human)	Potency	15.4706	AID686978; AID686979
glucocerebrosidase	Homo sapiens (human)	Potency	10.0000	AID2101
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	89.1251	AID504332
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	28.1838	AID540253
snurportin-1	Homo sapiens (human)	Potency	28.1838	AID540253
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	28.1838	AID540253
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	10.0000	AID588590
geminin	Homo sapiens (human)	Potency	7.5024	AID624296; AID624297
DNA dC->dU-editing enzyme APOBEC-3F isoform a	Homo sapiens (human)	Potency	6.3096	AID602313
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	17.7828	AID624288

Bioassays (7)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%

Substance	Classes	Roles	Relationship Strength
3-hydroxy-1-benzopyran-2-one	hydroxycoumarin		low
isoscopoletin	aromatic ether; hydroxycoumarin	plant metabolite	low
fraxin	aromatic ether; beta-D-glucoside; hydroxycoumarin	anti-inflammatory agent; hepatoprotective agent; plant metabolite	low
fraxetin	aromatic ether; hydroxycoumarin	anti-inflammatory agent; antibacterial agent; antimicrobial agent; antioxidant; apoptosis inducer; apoptosis inhibitor; Arabidopsis thaliana metabolite; hepatoprotective agent; hypoglycemic agent	low
scopoletin	hydroxycoumarin	plant growth regulator; plant metabolite	low
hymecromone	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor	low
daphnetin	hydroxycoumarin		low
daphnoretin	aromatic ether; hydroxycoumarin	antineoplastic agent; antiviral agent; metabolite	low
esculetin	hydroxycoumarin	antioxidant; plant metabolite; ultraviolet filter	low
esculin	beta-D-glucoside; hydroxycoumarin	antioxidant; metabolite	low
7-hydroxycoumarin	hydroxycoumarin	fluorescent probe; food component; plant metabolite	low
7-hydroxy-8-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-4-methyl-1-benzopyran-2-one	hydroxycoumarin		low
7-demethylsuberosin	hydroxycoumarin	plant metabolite	low
isofraxidin	hydroxycoumarin		low
4-methylesculetin	hydroxycoumarin	anti-inflammatory agent; antioxidant; hyaluronan synthesis inhibitor	low
osthenol	hydroxycoumarin	antifungal agent; plant metabolite	low
5,7-dihydroxy-4-methylcoumarin	hydroxycoumarin		low
7,8-dihydroxy-4-methylcoumarin	hydroxycoumarin		low
7-hydroxy-3-(4-methoxyphenyl)-4-methylcoumarin	hydroxycoumarin; monomethoxybenzene		low
2-(5,7-dihydroxy-4-methyl-2-oxo-1-benzopyran-3-yl)acetic acid ethyl ester	hydroxycoumarin		low
6-ethyl-7-hydroxy-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-1-benzopyran-2-one	hydroxycoumarin		low
3-bromo-7-hydroxy-4,8-dimethyl-1-benzopyran-2-one	hydroxycoumarin		low
5,7-dihydroxy-4-methyl-3-(phenylmethyl)-1-benzopyran-2-one	hydroxycoumarin		low
urolithin d	hydroxycoumarin		low
7-hydroxy-8-methyl-4-[[methyl-(phenylmethyl)amino]methyl]-1-benzopyran-2-one	hydroxycoumarin		low
3-(dimethylamino)benzoic acid (7-hydroxy-2-oxo-1-benzopyran-4-yl)methyl ester	hydroxycoumarin		low
3,8-dibromo-7-hydroxy-4-methylchromen-2-one	hydroxycoumarin		low
6-chloro-7-hydroxy-4-(4-morpholinylmethyl)-1-benzopyran-2-one	hydroxycoumarin		low
6-chloro-3-[2-[4-[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]-1-piperazinyl]-2-oxoethyl]-7-hydroxy-4-methyl-1-benzopyran-2-one	hydroxycoumarin		low
novobiocin	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent	low
dicumarol	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist	low
acenocoumarol	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor	low
warfarin	benzenes; hydroxycoumarin; methyl ketone		low
coumatetralyl	hydroxycoumarin		low
4,7-Dihydroxy-2H-1-benzopyran-2-one	hydroxycoumarin		low
7-(diethylamino)-4-hydroxy-1-benzopyran-2-one	hydroxycoumarin		low
phenprocoumon	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor	low
4'-hydroxywarfarin	hydroxycoumarin		low
7-hydroxywarfarin	hydroxycoumarin		low
coumachlor	hydroxycoumarin		low
4-hydroxycoumarin	hydroxycoumarin		low
ethyl biscoumacetate	hydroxycoumarin		low
4-hydroxy-3-(1-piperidinylmethyl)-1-benzopyran-2-one	hydroxycoumarin		low
10-hydroxywarfarin	hydroxycoumarin		low
pacific blue succinimidyl ester	hydroxycoumarin; N-hydroxysuccinimide ester; organofluorine compound	fluorochrome	low

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
Inflammation	0	1	2010	2010	14.0	high	0	0	0	1	0	0
Innate Inflammatory Response	0	1	2010	2010	14.0	high	0	0	0	1	0	0